Abivax Revenue and Competitors
Estimated Revenue & Valuation
- Abivax's estimated annual revenue is currently $11.9M per year.
- Abivax's estimated revenue per employee is $155,000
Employee Data
- Abivax has 77 Employees.
- Abivax grew their employee count by 51% last year.
Abivax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.6M | 81 | -5% | N/A | N/A |
#2 | $19.5M | 126 | -2% | N/A | N/A |
#3 | $36.3M | 234 | 22% | N/A | N/A |
#4 | $19.7M | 127 | -17% | N/A | N/A |
#5 | $14.3M | 92 | 0% | $179.5M | N/A |
#6 | $49.4M | 208 | -8% | €201.1M | N/A |
#7 | $44.5M | 287 | -3% | N/A | N/A |
#8 | $7.6M | 49 | N/A | N/A | N/A |
#9 | $6.4M | 41 | N/A | N/A | N/A |
#10 | $17.2M | 111 | -15% | N/A | N/A |
What Is Abivax?
Abivax is developing therapies that stimulate the body's natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body's natural immune system mechanisms to treat diseases. With several programs in clinical trials as well as in research and preclinical development, Abivax's pipeline is strong and diversified addressing many unmet medical needs. Abivax is currently targeting different inflammatory diseases within its clinical trial program with lead compound ABX464: 1) Treatment Inflammatory Bowel Disease (IBD), specifically ulcerative colitis and Crohn's disease 2) Treatment of rheumatoid arthritis 3) Prevention of severe of Covid-19 disease The second drug candidate, ABX196, is being tested in a clinical study for the treatment of liver cancer (HCC).
keywords:N/A
N/A
Total Funding
77
Number of Employees
$11.9M
Revenue (est)
51%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Abivax News
Abivax Sa; Arno Therapeutics Inc; Bharat Biotech International Ltd; Ennaid Therapeutics Llc; Etubics Corp; Hawaii Biotech Inc; Indian...
Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis.
Based on very promising Phase IIa results in rheumatoid arthritis, ABX464 is a compound that can potentially be used for the treatment of a...
Other Companies in Paris
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.9M | 77 | 5% | N/A |
#2 | $19.3M | 77 | -26% | N/A |
#3 | $23.5M | 77 | 24% | N/A |
#4 | $11.6M | 77 | 10% | N/A |
#5 | $11.2M | 77 | 35% | N/A |